ClariTrial — AI Clinical Trial Intelligence

Explore/cardiovascular heart disease trials recruiting Phase 2 Phase 3

Status

Phase

585 results for “cardiovascular heart disease trials recruiting Phase 2 Phase 3”

Page 1 of 39

NCT06328608

Recruiting

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Phase 2Phase 3Fabry Disease

PRX-102 1 mg/kg every two weeks

Chiesi Farmaceutici S.p.A.22 participants12 sites · United States, Austria, FranceCompletes Oct 2028

CT.gov Full analysis →

NCT07245069

Recruiting

Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

Phase 2Heart FailureAnthracycline-induced Cardiac ToxicityEndothelial Function (FMD)

Dapagliflozin 10 mgPlacebo

University Medical Centre Ljubljana100 participants1 site · SloveniaCompletes Nov 2028

CT.gov Full analysis →

NCT07381803

Recruiting

The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

Phase 3Zhejiang University

Fexofenadine 60 Mg Oral TabletPlacebo

Second Affiliated Hospital, School of Medicine, Zhejiang University2,804 participants1 site · ChinaCompletes Dec 2026

CT.gov Full analysis →

NCT04877197

Recruiting

Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care

Phase 3DepressionCardiovascular Diseases

BA-HTStandard Care

VA Office of Research and Development132 participants1 site · United StatesCompletes Jun 2026

CT.gov Full analysis →

NCT06833320

Recruiting

Propranolol Treatment for Postoperative Chylothorax

Phase 1Phase 2Postoperative ChylothoraxCongenital Heart DiseaseOpen Heart Surgery

Propranolol HydrochloridePlacebo

June Wu50 participants1 site · United StatesCompletes Sep 2028

CT.gov Full analysis →

NCT06516588

Recruiting

tDCS for Post-Stroke Cognitive Impairment

Phase 2StrokeMild Cognitive Impairment

Transcranial Dirrect Current Stimulation

University of Oklahoma80 participants1 site · United StatesCompletes Jun 2026

CT.gov Full analysis →

NCT06653569

Recruiting

Efficacy of Baloxavir Against Influenza in Hospitalized Patients: the INFLUENT Study (INpatients InFLUENza Treatment)

Phase 3Influenza Disease; Flu

Baloxavir MarboxilPlacebo

Dre Pauline Vetter484 participants1 site · SwitzerlandCompletes Apr 2027

CT.gov Full analysis →

NCT05054296

Recruiting

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

Phase 2Biochemically Recurrent Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8

Educational InterventionExercise InterventionFitBit+2 more

M.D. Anderson Cancer Center200 participants1 site · United StatesCompletes Feb 2027

CT.gov Full analysis →

NCT06563895

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Phase 3AmyloidosisAmyloid CardiomyopathyTransthyretin Amyloidosis

AcoramidisPlacebo oral tablet

Eidos Therapeutics, a BridgeBio company582 participants94 sites · United States, Argentina, AustraliaCompletes Oct 2031

CT.gov Full analysis →

NCT06686862

Recruiting

Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis

Phase 3Myocarditis Acute

ibuprofen

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III150 participants1 site · SpainCompletes Apr 2027

CT.gov Full analysis →

NCT05482945

Recruiting

CardioPulmonary Resuscitation With Argon (CPAr) Trial

Phase 2Cardiac Arrest, Out-Of-HospitalCardiac Arrest With Successful Resuscitation

Noble gas Argon

Mario Negri Institute for Pharmacological Research120 participants9 sites · ItalyCompletes Mar 2026

CT.gov Full analysis →

NCT04760717

Recruiting

Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke

Phase 2Intracerebral HemorrhageIschemic StrokeSpironolactone

Spironolactone Pill

Yale University200 participants5 sites · United StatesCompletes Dec 2025

CT.gov Full analysis →

NCT05925634

Recruiting

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

Phase 2Myocardial InfarctionCoronary Artery BypassPercutaneous Coronary Intervention

RPE (usual care)GXT+THHR (intervention)

Baystate Medical Center320 participants2 sites · United StatesCompletes Jul 2026

CT.gov Full analysis →

NCT07443293

Recruiting

IMPACT 360 for Parkinson's Disease

Phase 2Parkinson's Disease (PD)REM Sleep Behavior Disorder

ExerciseMeditationDiet

University of British Columbia60 participants1 site · CanadaCompletes May 2027

CT.gov Full analysis →

NCT05819138

Recruiting

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

Phase 3Diabetes Mellitus, Type 1

Semaglutide Pen InjectorPlacebo

University of Colorado, Denver60 participants2 sites · United StatesCompletes Oct 2027

CT.gov Full analysis →

1–15 of 585

Explore/cardiovascular heart disease trials recruiting Phase 2 Phase 3

Status

Phase

585 results for “cardiovascular heart disease trials recruiting Phase 2 Phase 3”

Page 1 of 39

NCT06328608

Recruiting

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Phase 2Phase 3Fabry Disease

PRX-102 1 mg/kg every two weeks

Chiesi Farmaceutici S.p.A.22 participants12 sites · United States, Austria, FranceCompletes Oct 2028

CT.gov Full analysis →

NCT07245069

Recruiting

Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

Phase 2Heart FailureAnthracycline-induced Cardiac ToxicityEndothelial Function (FMD)

Dapagliflozin 10 mgPlacebo

University Medical Centre Ljubljana100 participants1 site · SloveniaCompletes Nov 2028

CT.gov Full analysis →

NCT07381803

Recruiting

The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

Phase 3Zhejiang University

Fexofenadine 60 Mg Oral TabletPlacebo

Second Affiliated Hospital, School of Medicine, Zhejiang University2,804 participants1 site · ChinaCompletes Dec 2026

CT.gov Full analysis →

NCT04877197

Recruiting

Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care

Phase 3DepressionCardiovascular Diseases

BA-HTStandard Care

VA Office of Research and Development132 participants1 site · United StatesCompletes Jun 2026

CT.gov Full analysis →

NCT06833320

Recruiting

Propranolol Treatment for Postoperative Chylothorax

Phase 1Phase 2Postoperative ChylothoraxCongenital Heart DiseaseOpen Heart Surgery

Propranolol HydrochloridePlacebo

June Wu50 participants1 site · United StatesCompletes Sep 2028

CT.gov Full analysis →

NCT06516588

Recruiting

tDCS for Post-Stroke Cognitive Impairment

Phase 2StrokeMild Cognitive Impairment

Transcranial Dirrect Current Stimulation

University of Oklahoma80 participants1 site · United StatesCompletes Jun 2026

CT.gov Full analysis →

NCT06653569

Recruiting

Efficacy of Baloxavir Against Influenza in Hospitalized Patients: the INFLUENT Study (INpatients InFLUENza Treatment)

Phase 3Influenza Disease; Flu

Baloxavir MarboxilPlacebo

Dre Pauline Vetter484 participants1 site · SwitzerlandCompletes Apr 2027

CT.gov Full analysis →

NCT05054296

Recruiting

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

Phase 2Biochemically Recurrent Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8

Educational InterventionExercise InterventionFitBit+2 more

M.D. Anderson Cancer Center200 participants1 site · United StatesCompletes Feb 2027

CT.gov Full analysis →

NCT06563895

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Phase 3AmyloidosisAmyloid CardiomyopathyTransthyretin Amyloidosis

AcoramidisPlacebo oral tablet

Eidos Therapeutics, a BridgeBio company582 participants94 sites · United States, Argentina, AustraliaCompletes Oct 2031

CT.gov Full analysis →

NCT06686862

Recruiting

Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis

Phase 3Myocarditis Acute

ibuprofen

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III150 participants1 site · SpainCompletes Apr 2027

CT.gov Full analysis →

NCT05482945

Recruiting

CardioPulmonary Resuscitation With Argon (CPAr) Trial

Phase 2Cardiac Arrest, Out-Of-HospitalCardiac Arrest With Successful Resuscitation

Noble gas Argon

Mario Negri Institute for Pharmacological Research120 participants9 sites · ItalyCompletes Mar 2026

CT.gov Full analysis →

NCT04760717

Recruiting

Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke

Phase 2Intracerebral HemorrhageIschemic StrokeSpironolactone

Spironolactone Pill

Yale University200 participants5 sites · United StatesCompletes Dec 2025

CT.gov Full analysis →

NCT05925634

Recruiting

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

Phase 2Myocardial InfarctionCoronary Artery BypassPercutaneous Coronary Intervention

RPE (usual care)GXT+THHR (intervention)

Baystate Medical Center320 participants2 sites · United StatesCompletes Jul 2026

CT.gov Full analysis →

NCT07443293

Recruiting

IMPACT 360 for Parkinson's Disease

Phase 2Parkinson's Disease (PD)REM Sleep Behavior Disorder

ExerciseMeditationDiet

University of British Columbia60 participants1 site · CanadaCompletes May 2027

CT.gov Full analysis →

NCT05819138

Recruiting

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

Phase 3Diabetes Mellitus, Type 1

Semaglutide Pen InjectorPlacebo

University of Colorado, Denver60 participants2 sites · United StatesCompletes Oct 2027

CT.gov Full analysis →

1–15 of 585